Charisela Technologies, Inc. has introduced a new assay platform for flow cytometry. The assay platform's signature features include no wash and no dilution steps which improve assay precision and speed. Combining this assay platform with the benefits of flow cytometry will provide to the research (assay is currently research use only) community a practical and economical way to achieve more results faster.

Charisela's initial assay measures insulin, a polypeptide hormone with a molecular weight of 5800. It is the primary hormone responsible for conversion of glucose to glycogen and is secreted by special cells (Langerhans Cells) in the pancreas. Several physiological effects of insulin also serve to lower blood and tissue glucose levels. Inadequate secretion of insulin by the Islets of Langerhans result in elevated blood glucose levels leading to Type I Diabetes. Normal or elevated concentrations of insulin can be found in patients with Type II Diabetes, where resistance or insensitivity to insulin cause an increase in glucose levels. Advances in biotechnology has shown great progress in recombinant insulin production as well as in culturing and harvesting of insulin producing cells. Charisela’s Insulin assay is geared specifically for these institutions that yield high concentration insulin secretion via harvesting of these cells either for recombinant manufacturing or transplantation purposes.

For technical information please visit Technical Info. For purchasing info please visit Purchasing Info. For questions please contact Charlie d'Estries via email or telephone at +1-716-771-2899. For immediate response please complete the form by visitng Yes, Please Contact Me!